Identification of blood metabolites associated with risk of Alzheimer’s disease by integrating genomics and metabolomics data

Liu, Shuai; Zhong, Hua; Zhu, Jingjing; Wu, Lang

doi:10.1038/s41380-023-02400-9

Cited by 2 publications

(1 citation statement)

References 76 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Numerous studies have performed metabolome analysis for the definition of AD and PD biomarkers and the identification of potentially druggable targets ( Lista et al, 2023 ; Yin et al, 2023 ). Recently, Liu et al (2024) conducted a metabolome-wide association study in AD (MWAS) which led to the identification of fourteen metabolites showing an association with AD risk. de Lope et al (2024) identified PD-associated plasma metabolome alterations, particularly in xanthine metabolism, in line with other independent studies on transcriptomics data.…”

Section: Omics In Drug Discovery and Repurposing For Neurodegenerativ...mentioning

confidence: 99%

Tackling neurodegeneration in vitro with omics: a path towards new targets and drugs

Carraro,

Montgomery,

Klimmt

et al. 2024

Front. Mol. Neurosci.

View full text Add to dashboard Cite

Drug discovery is a generally inefficient and capital-intensive process. For neurodegenerative diseases (NDDs), the development of novel therapeutics is particularly urgent considering the long list of late-stage drug candidate failures. Although our knowledge on the pathogenic mechanisms driving neurodegeneration is growing, additional efforts are required to achieve a better and ultimately complete understanding of the pathophysiological underpinnings of NDDs. Beyond the etiology of NDDs being heterogeneous and multifactorial, this process is further complicated by the fact that current experimental models only partially recapitulate the major phenotypes observed in humans. In such a scenario, multi-omic approaches have the potential to accelerate the identification of new or repurposed drugs against a multitude of the underlying mechanisms driving NDDs. One major advantage for the implementation of multi-omic approaches in the drug discovery process is that these overarching tools are able to disentangle disease states and model perturbations through the comprehensive characterization of distinct molecular layers (i.e., genome, transcriptome, proteome) up to a single-cell resolution. Because of recent advances increasing their affordability and scalability, the use of omics technologies to drive drug discovery is nascent, but rapidly expanding in the neuroscience field. Combined with increasingly advanced in vitro models, which particularly benefited from the introduction of human iPSCs, multi-omics are shaping a new paradigm in drug discovery for NDDs, from disease characterization to therapeutics prediction and experimental screening. In this review, we discuss examples, main advantages and open challenges in the use of multi-omic approaches for the in vitro discovery of targets and therapies against NDDs.

show abstract

Section: Omics In Drug Discovery and Repurposing For Neurodegenerativ...mentioning

confidence: 99%

Tackling neurodegeneration in vitro with omics: a path towards new targets and drugs

Carraro,

Montgomery,

Klimmt

et al. 2024

Front. Mol. Neurosci.

View full text Add to dashboard Cite

show abstract

Identification of proteins associated with type 2 diabetes risk in diverse racial and ethnic populations

Liu,

Zhu,

Zhong

et al. 2024

Diabetologia

View full text Add to dashboard Cite

Identification of blood metabolites associated with risk of Alzheimer’s disease by integrating genomics and metabolomics data

Cited by 2 publications

References 76 publications

Tackling neurodegeneration in vitro with omics: a path towards new targets and drugs

Tackling neurodegeneration in vitro with omics: a path towards new targets and drugs

Identification of proteins associated with type 2 diabetes risk in diverse racial and ethnic populations

Contact Info

Product

Resources

About